Ironwood Pharmaceuticals | IRWD - Equity Capital And Reserves


Ironwood Pharmaceuticals reported $-217.14M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Almirall EUR 1.53B 43.26M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Astellas Pharma JPY 1.94T 113.64B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Charles River Laboratories USD 2.84B 59.06M Jun/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Moderna USD 6.76B 647M Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025